Open AccessHelicobacter pyloritherapy: Present and future
Author(s) -
De Francesco,
Enzo Ierardi,
Cesare Hassan,
Angelo Zullo
Publication year - 2012
Publication title -
world journal of gastrointestinal pharmacology and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2150-5349
DOI - 10.4292/wjgpt.v3.i4.68
Subject(s) - helicobacter pylori , medicine , gastritis , concomitant , pathogenesis , lymphoma , chronic gastritis , stomach , gastroenterology , gastric mucosa , immunology
Helicobacter pylori (H. pylori) plays a crucial role in the pathogenesis of chronic active gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue-lymphoma, and is also involved in carcinogenesis of the stomach. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. Several factors may help in the eradication of therapy failure. We reviewed both bacterial and host factors involved in therapeutic management of the H. pylori infection. In addition, we evaluated data on the most successful therapy regimens - sequential and concomitant therapies - currently available for H. pylori eradication.